Jiangsu Recbio Technology Co., Ltd. (2179.HK) HKSE
5.04
-0.06(-1.18%)
Currency In HKD
- General
- Statistics
- Historical Data
- Profile
- Financials
5.04
-0.06(-1.18%)
Currency In HKD
Sector
Healthcare
Industry
Biotechnology
Employees
531
First IPO Date
March 31, 2022
| Name | Title | Pay | Year Born |
| Yong Liu | Founder, Chief Executive Officer & Chairman of the Board | 1.64M | 1973 |
| Bu Li | Chief Human Resource Officer | 1.4M | 1977 |
| Kunxue Hong | Chief Science Officer | 1.57M | 1965 |
| Qingqing Chen | Chief Financial Officer, Joint Company Secretary & Executive Director | 1.57M | 1983 |
| Hongjun Zhou | Vice General Manager | 0 | 1981 |
| Kejian Yang | Senior Vice Vice President & Chief Technology Officer | 0 | 1966 |
| Lei Zhou | Finance controller | 0 | 1986 |
| Yang Zhou | Chief Operating Officer | 0 | 1981 |
| Jing Wang | Chief Quality Officer | 0 | 1977 |
| Mei Yee Yung | Joint Company Secretary | 0 | 1965 |
Jiangsu Recbio Technology Co., Ltd., a vaccine company, engages in the research, development, and commercialization of subunit vaccines in the People's Republic of China. The company is developing vaccines for the treatment of cervical cancer and genital warts, including REC603, a recombinant human papillomavirus (HPV) 9-valent vaccine that is in phase III clinical trial; REC601 and REC602 recombinant HPV bivalent vaccines, which are in phase I clinical trials; REC604a, a recombinant HPV quadrivalent vaccine that is in pre-clinical stage; and REC604b, a recombinant HPV 9-valent vaccine that is in pre-clinical stage. It is also developing ReCOV, a recombinant COVID-19 vaccine candidate that is in Phase II/III trial; and R520A, a messenger ribonucleic acid COVID-19 vaccine candidate that is in pre-clinical stage; REC610, a recombinant shingles vaccine that is in pre-clinical stage; REC607, a virus vectored adult tuberculosis vaccine that is in pre-clinical stage; REC606, a recombinant adult tuberculosis vaccine that is in pre-clinical stage; REC617, a recombinant influenza quadrivalent vaccine that is in pre-clinical stage; and REC605, a recombinant hand-foot-mouth disease quadrivalent vaccine that is in pre-clinical stage. The company was founded in 2011 and is based in Taizhou, the People's Republic of China.